Identifying and developing novel approaches to serious global health issues
We aim to radically improve the health of the global population through the successful treatment and prevention of our most serious chronic illnesses and life-threatening diseases.
Our Industry-leading expertise and deep relationships with research institutions in key regions around the globe leads to more rapid identification and development of novel treatments for emerging health issues.
We have experts in key regions around the globe who have deep relationships with the leading research institutions in those regions.
Site Focus
Site Focus
Key Partnerships
Site Focus
Key Partnerships
Site Focus:
Key Partnerships:
It takes skills in different disciplines to successfully bring a new treatment from concept and initial formulation through to a proven market ready product. We understand that, and have built a world leading team of recognized experts in their respective fields. What makes us stronger still are the relationships that our experts continue to foster with leading research institutions and partners around the globe.
Mr. Bom is the founder and Chairman of the board of Orion Biotechnology. Working closely with the CEO, Mr. Bom brings extensive international senior management experience from 17 years with Royal Philips electronics. He served as President and CEO for Philips in Singapore, Malaysia, Canada and China. Mr. Bom has also served as Chairman of the Management Board of Hagemeyer N.V., a Netherlands-based international trading company and as Managing Director of Al-Futtaim Dubai, one of the largest industrial and trading companies in the Middle East, active primarily in the Gulf
Mr. Groper is the Chief Executive Officer and a member of the Orion Biotechnology Board of Directors. He has more than 30 years of business and entrepreneurial experience in the Health Industry including founder and senior executive positions at both private and public sector organizations. Mr. Groper is a health industry expert with a proven track record of successfully building companies from start-up through to large scale commercial operations. He has held senior positions with Accenture, Telus Health, Emergis and DINMAR – a health care business he founded, operated, and grew to become a highly successful international business. Known as a results-oriented entrepreneur, with a demonstrated track record of success, Mr Groper provides leadership in strategic planning, and business development, while maintaining a keen focus on operational management. Mark has also built a strong reputation for innovation leadership, judgement and integrity, and understands what it takes to drive health care technologies into successful products
Mr. Klepatsky is the Chief Operating Officer and a member of the Orion Biotechnology Board of Directors. A senior executive with over 20 years of corporate management experience, Mr. Klepatsky has established success in corporate management, operations, and international business. Prior to joining Orion Biotechnology, he was a co-founder and Managing Partner of Altius, a leading Eastern European M&A firm with strong track record in healthcare, biotechnology and pharmaceutical industries. He has also served as Director of several private and public corporations in Eastern Europe and Canada. As the Chief Operating Officer at Orion, Mr. Klepatsky will lead business operations
Mr. Dmytro Martynenko has been a member of the Board of Directors of Novicol International Inc. since 2011 (legal predecessor to Orion Biotechnology) and has been practicing law for almost 25-years. He is on the Board of Directors for the Kviv International Airport and is legal advisor to the president of UDP (Ukrainian Development Partners) Group – a major shareholder of the Kyiv International Airport. and leading Ukraine real-estate development company. Before joining UDP Group, Dmytro worked for PricewaterhouseCoopers in Ukraine and Russia, and is a graduate of Kyiv National University Law School. Mr. Martynenko has broad experience in raising funds on financial markets, including private placements and IPOs, and has led major corporate structuring initiatives as well as cross border transactions.
Ian McGowan is the Chief Scientific Officer of Orion Biotechnology. Originally trained in medicine at the University of Liverpool, UK, Dr. McGowan also has doctoral degrees from Oxford University, UK in mucosal immunology and Liverpool University, UK in microbicide development. He is currently a Professor of Medicine at the University of Pittsburgh School of Medicine. Dr. McGowan has over 25 years dedicated to the development of antiretroviral drugs and vaccines for the treatment and prevention of HIV infection. He previously worked at Glaxo Wellcome on the development of amprenavir and abacavir and was also a Director of Clinical Research at Gilead Sciences Inc. where he was responsible for the Phase 2/3 development of tenofovir disoproxil fumarate for the treatment of HIV infection. As the former principle investigator of the NIH funded Microbicide Trials Network, he had responsibility for the oversight of a global program of Phase 1 through Phase 3 microbicide development. He has an extensive translational research portfolio focused on the discovery and development of microbicides and long acting injectable/implantable antiretroviral for HIV prevention. Dr. McGowan has served as a consultant for the U.S. Centers for Disease Control and Prevention, the World Health Organization, and is a former Chair of the United States Food and Drug Administration Antiviral Drugs Advisory Committee.
Mr. Jussup is the Chief Legal Counsel for Orion Biotechnology. Mr Jussup brings a background of broad experience in international business, intellectual property, corporate governance, mergers and acquisitions and securities law to his role at Orion Biotechnology. He received the Canadian General Counsel of the Year award, sponsored by The National Post and ZSA, in 2005, and holds the ICD.D designation from the Canadian Institute of Corporate Directors
With over 30 years experience in both the public markets and government sectors, he has been a corporate legal executive to leading technology companies as well as private and public sector institutions. Mr. Jussup was Senior Vice President, Chief Legal Officer & Secretary of Cognos Inc, Canada’s largest software company from 1993 until its acquisition by IBM in 2008. He later served as General Counsel & Secretary of the Bank of Canada from 2009 until 2012. He served as Chair of the Board of Keek Inc from 2013 until 2016 (listed on the TSX:V) and currently sits on the advisory board of PBC Real Estate Advisors, an Ottawa-based real estate investment fund. John Jussup has been a member of the Law Society of Ontario since 1977.
Mr. Engstrom is the Director of Clinical Operations at Orion Biotechnology responsible for design and implementation of the company’s early clinical development platform. Mr. Engstrom has extensive experience spanning preclinical strategy and operations, CRO/CMO oversight, translational research and FDA regulated Investigational New Drug (IND) programs. Mr. Engstrom started his career as a Clinical Research Assistant and quickly advanced through increasingly senior positions to Director of Clinical Operations. He has worked with a variety of health organizations including the University of Pittsburgh Magee Women’s Research Institute, NASORCAP Medical, and ARGEN Health. In his previous roles, Mr. Engstrom was principally responsible for operational oversight, management, and delivery of complex translational research protocols as well as managing the critical relationship between laboratories and clinical research centers. He will continue this work at Orion Biotechnology providing leadership and operational management for clinical activities, with the goal of rapidly bringing our novel technologies to market.
Dr. Offord has taught and researched at the Universities of Cambridge and Oxford, U.K. from 1962-1980, collaborating with, among others, the Nobel Prize winners Frederick Sanger, César Milstein, Dorothy Hodgkin and Aaron Klug. In 1980 he became a Departmental Director at the Faculty of Medicine, University of Geneva, and later served as President of the School of Basic Medicine there. Martin Rodbell (Nobel Prize 1994) was a visiting member of his group for two years in the early 1980s. Robin became an Emeritus Professor in October 2005. He was a co-founder of the Swiss Institute for Bioinformatics and is Chairman of the Advisory Board of Eclosion, Geneva’s life-sciences incubator. He served for ten years as a member of the Geneva government’s Council for Regional Economic Development. He is Chairman of the Board of Trustees of the Torrey Pines Institute for Molecular Studies (Port St Lucie, Florida and San Diego) and is the first non-US President of the American Peptide Society. Robin Offord shared the 2002 “Man of the Year, Switzerland” award of the Swiss financial newspaper L’agefi and in 2005 received the American Peptide Society’s Makineni Award. He is a co-founder of the Mintaka Foundation for Medical Research (2005) and is its Executive Director.
Dr. Hartley obtained his Ph.D at Cambridge, U.K., in 1997 in the group of Sir Gregory Winter. He has also researched into lysosomal storage disorders of children at the Institute of Child Health, London and in molecular biology at Glaxo-Wellcome. He has been at the Faculty of Medicine, University of Geneva, since 1997. He has been Principal Investigator under a number of competitively-won grants from agencies such as the US National Institutes of Health, the Swiss National Science Foundation and several private foundations in the US and Switzerland. He is a co-founder of the Mintaka Foundation for Medical Research (2005) and is its President and Chief Scientific Officer. He has shared a number of awards with Robin Offord in connection with their work for Mintaka. These include ‘Person of the Year 2008 – Culture’ of the ‘Tribune de Genève’; A Transitional Medicine Award of more than $4 million from the Wellcome Foundation (2010); the Jury Special Award of the Ashoka Impact Programme 2014; the “Prix de l’Innovation 2014” of CHF 10,000 from the Geneva University Hospitals and a second Translational Medicine Award of CHF ~3 million (2014)
Ms. Firestone joined the board of Orion Biotechnology in October of 2018, bringing with her extensive expertise in pharmaceutical and healthcare management. This has included government, retail, and various leadership roles with Pfizer inc., in Canada, Europe and Asia, with the latest being; Regional President, Asia Emerging Markets (Shanghai and HK). Theresa is currently Senior Vice President, Healthcare Businesses at Shoppers Drug Mart (SDM) and is responsible for several business units including MediSystem Pharmacies, Specialty Health Network, Pharmaceutical Partnerships, Shoppers Home Healthcare /Wellwise retail stores and Medical Cannabis. Ms. Firestone was a Corporate Director for Merus Labs International (TSE: MSL) from 2014-17 and has held board positions with several not-for-profit organizations. She is currently a board member with the Canadian Association for Pharmacy Distribution Management and the University of Guelph Board of Governors. Theresa was awarded the prestigious Queen’s Golden Jubilee Medal in 2002.
Since 2011 we have been developing a robust pipeline of potential products based on novel formulations discovered in different parts of the world. Our close ties to diverse institutions and experts around the globe continue to stimulate the rapid discovery of promising new treatments.
| Current Pipeline | Discovery | Preclinical | Phase I | Phase II |
|---|---|---|---|---|
| OB-001 Indication: Contraception & HIV prevention | ||||
| OB-002H Indication: HIV prevention | ||||
| OB-002M Indication: Multiple sclerosis | ||||
| OB-002O Indication: Oncology |
Tel: +1.343.291.1032
Contact Us
